Dr. Richards is from Cooper Medical School of Rowan University, Camden, New Jersey. Dr. Schimmel is from the Department of Dermatology, University of Colorado, Aurora. Dr. Renzi is from Dermatology Consultants, Lexington, Kentucky. Dr. Lawrence is from Cooper Dermatologic Surgery at Marlton, New Jersey.
Cutis. 2024 May;113(5):218-223. doi: 10.12788/cutis.1008.
Cutaneous angiosarcoma (CAS) is a rare aggressive malignancy that most commonly manifests in White men older than 60 years and often appears as an enlarging ecchymosis on the head, neck, or scalp. Surgery with negative margins is the first-line treatment. The role of Mohs micrographic surgery (MMS) is uncertain but can be used in smaller, well-circumscribed lesions on the head and neck. The greatest impact that dermatologists can have in the management of CAS is through a thorough total-body skin examination and heightened awareness resulting in a shortened time to diagnosis. Until quality evidence allows for the creation of consensus guidelines, multidisciplinary care at a cancer center that specializes in rare difficult-to-treat tumors is essential in optimizing patient outcomes.
皮肤血管肉瘤（cutaneous angiosarcoma，CAS）是一种罕见的侵袭性恶性肿瘤，最常见于 60 岁以上的白人男性，常表现为头部、颈部或头皮上逐渐增大的瘀斑。手术切除并保证切缘阴性是首选治疗方法。Mohs 显微外科手术（Mohs micrographic surgery，MMS）的作用尚不确定，但可用于头颈部较小、边界清楚的病变。皮肤科医生在 CAS 治疗中能发挥最大作用的方式是通过全面的全身皮肤检查和提高认识，从而缩短诊断时间。在高质量证据允许制定共识指南之前，在专门治疗罕见、难以治疗的肿瘤的癌症中心进行多学科治疗对于优化患者预后至关重要。
